EyePoint Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• EyePoint Pharmaceuticals Inc EYPT.OQ reported a quarterly adjusted loss of 85 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -100 cents to -55 cents per share.

• Revenue fell 43.7% to $5.33 million from a year ago; analysts expected $6.63 million.

• EyePoint Pharmaceuticals Inc's reported EPS for the quarter was a loss of 85 cents​.

• The company reported a quarterly loss of $59.43 million.

• EyePoint Pharmaceuticals Inc shares had risen by 15.7% this quarter and gained 46.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $27.50, about 60.4% above its last closing price of $10.89

This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)